Mortality and Thrombosis in Injured Adults Receiving Tranexamic Acid in the Post-CRASH-2 Era

INTRODUCTION: The CRASH-2 trial demonstrated that tranexamic acid (TXA) reduced mortality with no increase in adverse events in severely injured adults. TXA has since been widely used in injured adults worldwide. Our objective was to estimate mortality and adverse events in adults with trauma receiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Benipal, Simranjeet, Santamarina, John-Lloyd, Vo, Linda, Nishijima, Daniel K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Department of Emergency Medicine, University of California, Irvine School of Medicine 2019
Materias:
Trauma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526890/
https://www.ncbi.nlm.nih.gov/pubmed/31123544
http://dx.doi.org/10.5811/westjem.2019.4.41698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526890/
https://www.ncbi.nlm.nih.gov/pubmed/31123544
http://dx.doi.org/10.5811/westjem.2019.4.41698

Ejemplares similares